Targeted radionuclide therapy of neuroendocrine tumors using PB212-octreotate analogs

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201600015C
Awardee
Awarding agency
Obligated
$298,132

Award facts

Opportunity
  • PHS20161 Solicitation number
Contract value 100% obligated
$298,132.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 12 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Houston, TX 77042, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 2 $0
Other Administrative Action 1 $0
Original award $298,132

About this award

This contract was awarded by the National Cancer Institute, a civilian agency, to Radiomedix, Inc., a small disadvantaged business, for the Targeted Radionuclide Therapy of Neuroendocrine Tumors Using Pb212-Octreotate Analogs project. The contract has a ceiling value of $298,132.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has an ultimate completion date of August 18, 2017.

Quick answers

Who was awarded contract HHSN261201600015C?

HHSN261201600015C was awarded to Radiomedix, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600015C worth?

The government has obligated $298,132 on HHSN261201600015C.

Was contract HHSN261201600015C competed?

The extent of competition for HHSN261201600015C was full and open competition after exclusion of sources. The government received 12 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award